PRCM
IPXL

Pine River Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Pine River Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-13,541
Closed -$434K – 647
2016
Q1 		$434K Buy
+13,541
New +$476K 0.01% 580

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pine River Capital Management's IPXL Position: Q2 2016 in Review

Pine River Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2016, closing a stake of 13,541 shares — an estimated $434K sold.

Pine River Capital Management first reported a position in IPXL in Q1 2016 and held it in 1 quarter. The position peaked at $434K in Q1 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q2 2016.

  • Pine River Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2016 after selling out during the quarter.
  • Pine River Capital Management sold 13,541 Impax Laboratories, Inc. shares in Q2 2016, an estimated $434K.
  • Pine River Capital Management first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 1 quarter.
  • Pine River Capital Management's Impax Laboratories, Inc. position peaked at $434K in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2016.

Based on Pine River Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.